These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 10561240)

  • 21. [Nausea after cisplatin administration can be prevented with antiemetic treatment].
    Ohlsson R; Steineck G; Peterson C
    Lakartidningen; 1986 Dec; 83(52):4455-7. PubMed ID: 3821302
    [No Abstract]   [Full Text] [Related]  

  • 22. [Emesis induced by cisplatin and sulfato-1, sulfato-1,2-diaminocyclohexane platinum in dogs and their antiemetics].
    Huo ML; Wang YS; Wang P; Xiang YS; Wang JG
    Zhongguo Yao Li Xue Bao; 1986 Mar; 7(2):182-4. PubMed ID: 2946163
    [No Abstract]   [Full Text] [Related]  

  • 23. Antiemetics: an update and the MASCC guidelines applied in clinical practice.
    Herrstedt J
    Nat Clin Pract Oncol; 2008 Jan; 5(1):32-43. PubMed ID: 18097455
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Broad-spectrum antiemetic potential of the L-type calcium channel antagonist nifedipine and evidence for its additive antiemetic interaction with the 5-HT(3) receptor antagonist palonosetron in the least shrew (Cryptotis parva).
    Darmani NA; Zhong W; Chebolu S; Vaezi M; Alkam T
    Eur J Pharmacol; 2014 Jan; 722():2-12. PubMed ID: 24513517
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial.
    Grunberg SM; Rolski J; Strausz J; Aziz Z; Lane S; Russo MW; Wissel P; Guckert M; Wright O; Herrstedt J
    Lancet Oncol; 2009 Jun; 10(6):549-58. PubMed ID: 19428297
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chemotherapy-induced nausea and vomiting: antiemetic trials that impacted clinical practice.
    Trigg ME; Higa GM
    J Oncol Pharm Pract; 2010 Dec; 16(4):233-44. PubMed ID: 20085961
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Management of vomiting associated with cytotoxic therapy.
    Jones AL; Cunningham D
    Br J Hosp Med; 1991 Feb; 45(2):85-8. PubMed ID: 2018889
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ondansetron (GR 38032F): a novel antiemetic effective in patients receiving a multiple-day regimen of cisplatin chemotherapy.
    Hainsworth JD; Omura GA; Khojasteh A; Bryson JC; Finn AL
    Am J Clin Oncol; 1991 Aug; 14(4):336-40. PubMed ID: 1830716
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antiemetic role of thalidomide in a rat model of cisplatin-induced emesis.
    Han ZX; Xu J; Wang HM; Ma J; Sun X; Du XP
    Cell Biochem Biophys; 2014 Sep; 70(1):361-5. PubMed ID: 24718779
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antiemetics for patients treated with antitumor chemotherapy.
    Williams CJ; Bolton A; de Pemberton R; Whitehouse JM
    Cancer Clin Trials; 1980; 3(4):363-7. PubMed ID: 6253100
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Evaluation of antiemetic effect of clonazepam, metoclopramide, dexamethasone and diphenhydramine for prevention of cisplatin-induced vomiting].
    Hatae M; Nakamura Y; Mitsuo M; Sakurai K; Asano H; Onishi Y; Hokanishi H
    Gan To Kagaku Ryoho; 1990 Aug; 17(8 Pt 1):1495-9. PubMed ID: 2389945
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antiemetic therapy of fosaprepitant, palonosetron, and dexamethasone combined with cisplatin-based chemotherapy for head and neck carcinomas.
    Tsukahara K; Nakamura K; Motohashi R; Sato H; Endo M; Katsube Y; Ueda Y; Suzuki M
    Acta Otolaryngol; 2014 Nov; 134(11):1198-204. PubMed ID: 25315920
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reliability of videotape technology in assessing the efficacy of anti-emetic drugs.
    Triplett WC; Schroeder JE; Minnick DJ; Dugan WM; Berry JA
    Prog Clin Biol Res; 1986; 216():377-84. PubMed ID: 3523533
    [No Abstract]   [Full Text] [Related]  

  • 34. Management of nausea and vomiting caused by anticancer drugs: state of the art.
    Pisters KM; Kris MG
    Oncology (Williston Park); 1992 Feb; 6(2 Suppl):99-104. PubMed ID: 1532744
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy & tolerability of ondansetron compared to metoclopramide in dose dependent cisplatin-induced delayed emesis.
    Bhatia A; Tripathi KD; Sharma M
    Indian J Med Res; 2004 Sep; 120(3):183-93. PubMed ID: 15489556
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A new class of antiemetic agents on the horizon.
    Rittenberg CN
    Clin J Oncol Nurs; 2002; 6(2):103-4. PubMed ID: 11889671
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chemotherapy-induced nausea and vomiting: current and new standards in the antiemetic prophylaxis and treatment.
    Jordan K; Kasper C; Schmoll HJ
    Eur J Cancer; 2005 Jan; 41(2):199-205. PubMed ID: 15661543
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Optimal use of antiemetics in the outpatient setting.
    Grunberg SM
    Oncology (Williston Park); 2002 Oct; 16(10):1401-7; discussion 1407-8, 1412. PubMed ID: 12435208
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Easy method for emesis using rats].
    Saito R; Takano Y
    Nihon Yakurigaku Zasshi; 2006 Jun; 127(6):461-6. PubMed ID: 16880696
    [No Abstract]   [Full Text] [Related]  

  • 40. Studies on new antiemetic drugs.
    Roila F; Tonato M; Ballatori E; Del Favero A
    J Clin Oncol; 1999 Jun; 17(6):1960-2. PubMed ID: 10561240
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.